|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
1,430,000,000 |
Market
Cap: |
106.75(B) |
Last
Volume: |
6,978,222 |
Avg
Vol: |
8,439,653 |
52
Week Range: |
$48.64 - $74.55 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 297 |
Guru Rank Value : 4.1 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Boston Scientific develops, manufactures and markets medical devices. Co.'s Medical Surgical segment consist of: Endoscopy, which develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions; and Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions. Co.'s Rhythm and Neuro segment includes: Cardiac Rhythm Management, which develops and manufactures implantable devices to treat cardiac abnormalities; and Electrophysiology, which develops and manufactures medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
131,028 |
294,034 |
784,747 |
1,896,260 |
Total Sell Value |
$9,081,880 |
$18,529,068 |
$44,400,077 |
$93,901,157 |
Total People Sold |
8 |
9 |
11 |
13 |
Total Sell Transactions |
13 |
22 |
38 |
73 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Burns Brian R |
EVP - Global Quality & Reg Aff |
|
2011-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,748 |
56,687 |
|
- |
|
Dawkins Keith D |
Sr. VP, Chief Medical Officer |
|
2011-02-16 |
4 |
D |
$7.10 |
$7,611 |
D/D |
(1,072) |
46,148 |
|
- |
|
Dawkins Keith D |
Sr. VP, Chief Medical Officer |
|
2011-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,374 |
47,220 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, Endovascular |
|
2011-02-16 |
4 |
D |
$7.10 |
$11,346 |
D/D |
(1,598) |
49,902 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, Endovascular |
|
2011-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,724 |
51,500 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2011-02-16 |
4 |
D |
$7.10 |
$46,441 |
D/D |
(6,541) |
83,000 |
|
- |
|
Capello Jeffrey D |
EVP & Chief Financial Officer |
|
2011-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,244 |
89,541 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, Endovascular |
|
2011-02-14 |
4 |
D |
$6.97 |
$12,651 |
D/D |
(1,815) |
46,776 |
|
- |
|
Fitzgerald Joseph Michael |
SVP & President, Endovascular |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,916 |
48,591 |
|
- |
|
Onuscheck John Michael |
SVP & Pres-Neuromodulation |
|
2011-02-14 |
4 |
D |
$6.97 |
$16,519 |
D/D |
(2,370) |
34,019 |
|
- |
|
Onuscheck John Michael |
SVP & Pres-Neuromodulation |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,628 |
36,389 |
|
- |
|
Kucheman William |
EVP, & Group Pres, CRV |
|
2011-02-14 |
4 |
D |
$6.97 |
$10,009 |
D/D |
(1,436) |
57,123 |
|
- |
|
Kucheman William |
EVP, & Group Pres, CRV |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,993 |
58,559 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2011-02-14 |
4 |
D |
$6.97 |
$12,330 |
D/D |
(1,769) |
74,398 |
|
- |
|
Pucel Kenneth |
EVP, Global Ops & Technology |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,792 |
76,167 |
|
- |
|
Phalen Michael P. |
EVP & President, International |
|
2011-02-14 |
4 |
D |
$6.97 |
$8,211 |
D/D |
(1,178) |
32,487 |
|
- |
|
Phalen Michael P. |
EVP & President, International |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,274 |
33,665 |
|
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2011-02-14 |
4 |
D |
$6.97 |
$2,502 |
D/D |
(359) |
639 |
|
- |
|
Pedersen John B. |
Pres, Uro & Womens Health |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
998 |
998 |
|
- |
|
Leno Sam R |
EVP & Chief Operations Officer |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,982 |
344,470 |
|
- |
|
Moreci Stephen F |
SVP, Global Sales Operations |
|
2011-02-14 |
4 |
D |
$6.97 |
$7,507 |
D/D |
(1,077) |
28,555 |
|
- |
|
Moreci Stephen F |
SVP, Global Sales Operations |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,995 |
29,632 |
|
- |
|
Lance Jean Fitterer |
SVP & Chief Compliance Officer |
|
2011-02-14 |
4 |
D |
$6.97 |
$8,218 |
D/D |
(1,179) |
55,850 |
|
- |
|
Lance Jean Fitterer |
SVP & Chief Compliance Officer |
|
2011-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,194 |
57,029 |
|
- |
|
Burns Brian R |
EVP - Global Quality & Reg Aff |
|
2011-02-14 |
4 |
D |
$6.97 |
$10,009 |
D/D |
(1,436) |
49,939 |
|
- |
|
1828 Records found
|
|
Page 29 of 74 |
|
|